RA
VKTX icon

RFG Advisory’s Viking Therapeutics VKTX Stock Holding History

RFG Advisory’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.57M Buy
142,790
+463
+0.3% +$15K 0.09% 158
2026
Q1 		$4.63M Sell
142,327
-1,233
-0.9% -$39.6K 0.09% 171
2025
Q4 		$5.05M Buy
143,560
+23,346
+19% +$827K 0.1% 160
2025
Q3 		$3.16M Buy
120,214
+55,175
+85% +$1.65M 0.07% 227
2025
Q2 		$1.72M Buy
65,039
+25,387
+64% +$668K 0.04% 339
2025
Q1 		$958K Buy
+39,652
New +$1.25M 0.03% 412

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

RFG Advisory's VKTX Position: Q2 2026 in Review

RFG Advisory increased its Viking Therapeutics (VKTX) stake by 0.33% in Q2 2026, buying an estimated $15K and bringing the position to 142,790 shares worth $5.57M. The position accounts for 0.09% of the portfolio, ranked #158.

RFG Advisory first reported a position in VKTX in Q1 2025 and has held it in 6 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • RFG Advisory held 142,790 shares of Viking Therapeutics worth $5.57M as of Q2 2026.
  • RFG Advisory bought 463 Viking Therapeutics shares in Q2 2026, an estimated $15K.
  • Viking Therapeutics made up 0.09% of RFG Advisory's portfolio in Q2 2026, its #158 holding.
  • RFG Advisory first reported a position in Viking Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on RFG Advisory's 13F filing for Q2 2026, filed 15 Jul 2026.